Joan Albanell

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

José Baselga, Larry Norton, Joan Albanell et al. · PubMed · 1998 · 1K citations

Her2-overexpressing Cancer Cells, Antitumor Activity, Breast Oncology +14

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

José Baselga, Danny Rischin, Malcolm Ranson et al. · Journal of Clinical Oncology · 2002 · 829 citations

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

Jordi Codony‐Servat, Joan Albanell, Federico Rojo et al. · PubMed · 2001 · 775 citations

Her2 Ectodomain Cleavage, Breast Oncology, Biochemistry +15

A SNAIL1–SMAD3/4 transcriptional repressor complex promotes TGF-β mediated epithelial–mesenchymal transition

C. Theresa Vincent, Etienne P.A. Neve, Jill R. Johnson et al. · Nature Cell Biology · 2009 · 631 citations · Full text

Epithelial-mesenchymal Transition, Transcriptional Regulation, Developmental Biology +12

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations

David Tamborero, Carlota Rubio-Pérez, Jordi Deu-Pons et al. · Genome Medicine · 2018 · 534 citations · Full text